Diagnostic challenge of delayed immune-related hepatitis during zongertinib treatment after nivolumab plus ipilimumab in a 52-year-old man with HER2-mutant non-small cell lung cancer: a case report.
- 1Department of Respiratory Medicine, Japanese Red Cross Saitama Hospital, Saitama, Japan.
- 2Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Abstract
Delayed immune-related hepatitis after discontinuation of immune checkpoint inhibitors (ICIs) is increasingly recognized, but attribution is difficult when liver injury develops during subsequent tyrosine kinase inhibitor (TKI) therapy. This diagnostic dilemma has not been well described during human epidermal growth factor receptor 2 (HER2)-selective TKI treatment after dual ICI therapy. A 52-year-old Japanese man with HER2 exon 20 insertion-positive stage IVB non-small cell lung cancer received nivolumab plus ipilimumab from February 28 to November 13, 2025, and developed grade 2 oral mucositis, grade 2 adrenal insufficiency, and grade 1-2 skin toxicity. Zongertinib was initiated on November 26. Routine testing on January 6, 2026 showed grade 3 hepatocellular injury, and zongertinib was withheld. Despite drug withdrawal, liver injury progressed, and he was admitted with mild fatigue on January 20, when aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and γ-glutamyl transpeptidase levels were 774, 1,386, 156, and 160 U/L, respectively. Total bilirubin remained approximately 1.0 mg/dL. Viral and autoimmune testing and imaging disclosed no alternative cause. Liver biopsy showed active hepatitis with lymphocyte-predominant portal and lobular inflammation and interface activity, findings compatible with an immune-mediated hepatitis pattern but not specific for the causative agent. Prednisolone 40 mg/day (approximately 0.5 mg/kg/day) produced rapid biochemical improvement with resolution of fatigue. Zongertinib was resumed on February 11 and continued without recurrent hepatitis through June 2026. The progression of liver injury despite zongertinib withdrawal, multiple prior immune-related adverse events, exclusion of competing causes, compatible histology, corticosteroid responsiveness, and absence of recurrence after zongertinib rechallenge collectively favored delayed immune-related hepatitis, although zongertinib-associated drug-induced liver injury could not be completely excluded. In similar cases, a structured etiological assessment, including liver biopsy when the result may alter cancer treatment, can help guide management.
Related
- Immunization with an Escherichia coli-Produced Hepatitis E Virus Genotype 3 Virus-like Particle (HEV-3_p495) Confers Protection Against HEV-3 and HEV-4 Challenge in Pigs.
- Diagnostic challenge of pulmonary embolism during testosterone replacement therapy for primary hypogonadism
- Giant primary retroperitoneal myxofibrosarcoma mimicking myxoid liposarcoma: a diagnostic and surgical challenge
- Relapsing Polychondritis With Severe Airway Involvement Mimicking Refractory Asthma: A Diagnostic Challenge
- Diagnostic Challenge in Cytology: Fibrosing Thyroiditis Mimicking Medullary Thyroid Carcinoma.
BibTeX
@article{oba2026diagnostic,
title = {{Diagnostic challenge of delayed immune-related hepatitis during zongertinib treatment after nivolumab plus ipilimumab in a 52-year-old man with HER2-mutant non-small cell lung cancer: a case report.}},
author = {Tomohiro Oba and Shunya Shiohira and Yoko Machida and Daisuke Nakatani and Keiichi Akasaka and Masako Amano and Hidekazu Matsushima},
journal = {Translational lung cancer research},
year = {2026},
month = sep,
doi = {10.21037/tlcr-2026-0856},
url = {https://europepmc.org/article/MED/42999648},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Diagnostic challenge of delayed immune-related hepatitis during zongertinib treatment after nivolumab plus ipilimumab in a 52-year-old man with HER2-mutant non-small cell lung cancer: a case report.
AU - Tomohiro Oba
AU - Shunya Shiohira
AU - Yoko Machida
AU - Daisuke Nakatani
AU - Keiichi Akasaka
AU - Masako Amano
AU - Hidekazu Matsushima
PY - 2026
DA - 2026/09/29
JO - Translational lung cancer research
DO - 10.21037/tlcr-2026-0856
UR - https://europepmc.org/article/MED/42999648
AB - Delayed immune-related hepatitis after discontinuation of immune checkpoint inhibitors (ICIs) is increasingly recognized, but attribution is difficult when liver injury develops during subsequent tyrosine kinase inhibitor (TKI) therapy. This diagnostic dilemma has not been well described during human epidermal growth factor receptor 2 (HER2)-selective TKI treatment after dual ICI therapy. A 52-year-old Japanese man with HER2 exon 20 insertion-positive stage IVB non-small cell lung cancer received nivolumab plus ipilimumab from February 28 to November 13, 2025, and developed grade 2 oral mucositis, grade 2 adrenal insufficiency, and grade 1-2 skin toxicity. Zongertinib was initiated on November 26. Routine testing on January 6, 2026 showed grade 3 hepatocellular injury, and zongertinib was withheld. Despite drug withdrawal, liver injury progressed, and he was admitted with mild fatigue on January 20, when aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and γ-glutamyl transpeptidase levels were 774, 1,386, 156, and 160 U/L, respectively. Total bilirubin remained approximately 1.0 mg/dL. Viral and autoimmune testing and imaging disclosed no alternative cause. Liver biopsy showed active hepatitis with lymphocyte-predominant portal and lobular inflammation and interface activity, findings compatible with an immune-mediated hepatitis pattern but not specific for the causative agent. Prednisolone 40 mg/day (approximately 0.5 mg/kg/day) produced rapid biochemical improvement with resolution of fatigue. Zongertinib was resumed on February 11 and continued without recurrent hepatitis through June 2026. The progression of liver injury despite zongertinib withdrawal, multiple prior immune-related adverse events, exclusion of competing causes, compatible histology, corticosteroid responsiveness, and absence of recurrence after zongertinib rechallenge collectively favored delayed immune-related hepatitis, although zongertinib-associated drug-induced liver injury could not be completely excluded. In similar cases, a structured etiological assessment, including liver biopsy when the result may alter cancer treatment, can help guide management.
SN - 2218-6751
SN - 2226-4477
ER -